The muscarinic antagonist scopolamine produces rapid antidepressant effects in individuals with major depressive disorder (MDD). In healthy subjects, manipulation of acetyl-cholinergic transmission modulates attention in a stimulus-dependent manner. This study tested the hypothesis that baseline amygdalar activity in response to emotional stimuli correlates with antidepressant treatment response to scopolamine and could thus potentially predict treatment outcome. MDD patients and healthy controls performed an attention shifting task involving emotional faces while undergoing functional magnetic resonance imaging (fMRI). We found that blood oxygenation level dependent (BOLD) signal in the amygdala acquired while MDD patients processed sad face stimuli correlated positively with antidepressant response to scopolamine. Amygdalar response to sad faces in MDD patients who did not respond to scopolamine did not differ from that of healthy controls. This suggests that the pre-treatment task elicited amygdalar activity that may constitute a biomarker of antidepressant treatment response to scopolamine. Furthermore, in MDD patients who responded to scopolamine, we observed a post-scopolamine stimulus processing shift towards a pattern demonstrated by healthy controls, indicating a change in stimulus-dependent neural response potentially driven by attenuated cholinergic activity in the amygdala.
a b s t r a c t
The muscarinic antagonist scopolamine produces rapid antidepressant effects in individuals with major depressive disorder (MDD). In healthy subjects, manipulation of acetyl-cholinergic transmission modulates attention in a stimulus-dependent manner. This study tested the hypothesis that baseline amygdalar activity in response to emotional stimuli correlates with antidepressant treatment response to scopolamine and could thus potentially predict treatment outcome. MDD patients and healthy controls performed an attention shifting task involving emotional faces while undergoing functional magnetic resonance imaging (fMRI). We found that blood oxygenation level dependent (BOLD) signal in the amygdala acquired while MDD patients processed sad face stimuli correlated positively with antidepressant response to scopolamine. Amygdalar response to sad faces in MDD patients who did not respond to scopolamine did not differ from that of healthy controls. This suggests that the pre-treatment task elicited amygdalar activity that may constitute a biomarker of antidepressant treatment response to scopolamine. Furthermore, in MDD patients who responded to scopolamine, we observed a post-scopolamine stimulus processing shift towards a pattern demonstrated by healthy controls, indicating a change in stimulus-dependent neural response potentially driven by attenuated cholinergic activity in the amygdala.
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Introduction
Major depressive disorder (MDD) affects approximately 4.7% of the global population at any given time (Ferrari et al., 2013) and is one of the leading causes of disability in the United States (Kessler, 2012) . Although many therapeutic options exist for patients diagnosed with MDD, the rate of treatment response is variable and remains difficult to predict. Thus, identifying biomarkers of treatment response could both minimize participation in trials not likely to succeed and significantly reduce time to relief from depressive symptoms and the restoration of social and occupational functioning for those patients who do respond (Insel, 2009; Luyten et al., 2006; Machado-Vieira et al., 2009; Simon and Perlis, 2010) . Given their enormous public health implications, biomarkers of treatment response are being widely pursued, and several have been tentatively identified in multiple domains (Breitenstein et al., 2014; Schmidt et al., 2011; Siegle et al., 2006) . However, it remains unclear whether the biomarkers are specific to a particular intervention, or whether they identify subjects more likely to respond to treatment in general. Nevertheless, improving our ability to predict treatment response for specific patient profiles, as well as identifying rapid-acting medications, is key to improving clinical outcomes (Zarate et al., 2013) .
Clinical trials found that the muscarinic cholinergic antagonist scopolamine exerts significant antidepressant effects within three days of treatment administration in depressed patients with either MDD or bipolar disorder (Drevets and Furey, 2010; Furey and Drevets, 2006) . Specifically, approximately half of patients treated with scopolamine experienced remission, and 65% achieved clinical response after a relatively short treatment period (three infusions over approximately two weeks). Several potential predictors of antidepressant response to scopolamine have been identified; these include baseline mood-state measures (Furey Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/psychresns
